Skip to main content
PLOS One logoLink to PLOS One
. 2022 Apr 20;17(4):e0267122. doi: 10.1371/journal.pone.0267122

Maternal body composition and gestational weight gain in relation to asthma control during pregnancy

Danielle R Stevens 1, Matthew C H Rohn 1, Stefanie N Hinkle 1, Andrew D Williams 2, Rajesh Kumar 3, Leah M Lipsky 1, William Grobman 3, Seth Sherman 4, Jenna Kanner 1, Zhen Chen 1, Pauline Mendola 1,5,*
Editor: Kelli K Ryckman6
PMCID: PMC9020691  PMID: 35442986

Abstract

Background

Poor asthma control is common during pregnancy and contributes to adverse pregnancy outcomes. Identification of risk factors for poor gestational asthma control is crucial.

Objective

Examine associations of body composition and gestational weight gain with asthma control in a prospective pregnancy cohort (n = 299).

Methods

Exposures included pre-pregnancy body mass index (BMI), first trimester skinfolds, and trimester-specific gestational weight gain. Outcomes included percent predicted forced expiratory volumes (FEV1, FEV6), forced vital capacity (FVC), peak expiratory flow (PEF), FEV1/FVC, symptoms (activity limitation, nighttime symptoms, inhaler use, and respiratory symptoms), and exacerbations (asthma attacks, medical encounters). Linear and Poisson models examined associations with lung function (β (95% confidence interval (CI)), asthma symptom burden (relative rate ratio (RR (95%CI)), and exacerbations (RR (95%CI)).

Results

Women with a BMI ≥ 30 had lower percent predicted FVC across pregnancy (βThirdTrimester: -5.20 (-8.61, -1.78)) and more frequent night symptoms in the first trimester (RR: 1.66 (1.08, 2.56)). Higher first trimester skinfolds were associated with lower FEV1, FEV6, and FVC, and more frequent night symptoms and inhaler use across pregnancy. Excessive first trimester gestational weight gain was associated with more frequent activity limitation in the first trimester (RR: 3.36 (1.15, 9.80)) and inhaler use across pregnancy (RRThirdTrimester: 3.49 (1.21, 10.02)).

Conclusions

Higher adiposity and first trimester excessive gestational weight gain were associated with restrictive changes in lung function and symptomology during pregnancy.

Introduction

Asthma complicates approximately 10% of U.S. pregnancies, and has been associated with higher rates of adverse pregnancy outcomes [15]. In pregnancies affected by asthma, adequate asthma control may mitigate adverse pregnancy outcomes [6]. However, about a third of women experience deterioration in asthma control throughout pregnancy, and risk factors for inadequate asthma control during pregnancy have not been well-elucidated [7].

Evidence suggests that obesity and weight gain may be associated with changes in asthma development or control in non-pregnant populations [814]. Pre-pregnancy obesity and excess gestational weight gain may contribute to decrements in asthma control throughout pregnancy via mechanical restriction of lung volume, cardiometabolic disruption, and inflammation [15]. A few prior studies have examined associations between pre-pregnancy body mass index (BMI), gestational weight gain, and asthma exacerbations during pregnancy, with discordant results [1620]. Further, asthma control is assessed based on exacerbation risk and symptomology; only one prior study has examined maternal pre-pregnancy BMI and gestational weight gain associated with asthma control based on symptomology during pregnancy [20, 21]. Contrary to hypotheses, this study reported that increased total gestational weight gain was associated with decreased risk of recurrent uncontrolled asthma [20].

These few prior studies also have several notable limitations. First, they frequently lack trimester-specific information, which may help guide clinical decision-making and knowledge of underlying biologic pathways. Second, prior studies do not include spirometry, despite its inclusion in many asthma control guidelines and its clinical utility [22]. Third, measures of body composition such as subscapular (central) or triceps (regional) skinfolds are more sensitive measures of body fatness than BMI [23]; prior studies lack these more sensitive measures. Finally, existing studies do not include a control group of women without asthma to assess whether associations are unique to women with asthma. Given the contrasting literature and limitations to prior research, further study of this association is needed.

The primary aim of this study was to examine maternal body composition and gestational weight gain in relation to gestational asthma control in the Breathe—Wellbeing, Environment, Lifestyle, and Lung Function (B-WELL-Mom) cohort. We hypothesized that higher adiposity (i.e., pre-pregnancy BMI and skinfold thicknesses) and excessive gestational weight gain would contribute to poorer lung function and more frequent asthma symptoms and exacerbations during pregnancy.

Materials and methods

Study design

Participants were part of the B-WELL-Mom study, a prospective pregnancy cohort of women with active asthma (n = 311) or no history of asthma (n = 107). Women with and without asthma were recruited from two US-based study sites (Northwestern University in Chicago and the University of Alabama at Birmingham) during 2015–2019. Medical record review was used to identify potentially eligible participants, who were then screened for eligibility (S1 Table) and consent. Women were followed across pregnancy with three in-person clinical assessments of lung function and questionnaires completed at 6–14 weeks gestation (visit 1), 20–22 weeks gestation (visit 2), and 30–32 weeks gestation (visit 3). Study procedures also included daily diaries and medical record abstraction throughout pregnancy. Data collection was for research purposes only and was not used to direct clinical management of asthma. Study materials are available on the B-WELL-Mom website (https://b-well-mom.org) and in the supporting information (baseline questionnaire in S1 File, visits 2 and 3 questionnaire in S2 File, and daily diary questions in S3 File). Questionnaires were based on existing asthma control assessments [21, 24, 25] and were thus not validated prior to use on study participants. Human subjects’ approval was obtained from all participating sites and all subjects provided written informed consent.

Outcome assessment

According to asthma control guidelines, asthma control is typically assessed based on exacerbation risk and symptomology [21, 24, 26]. Lung function is not consistently employed across asthma control guidelines but plays a key role in asthma control assessment in clinical practice [21, 24, 26]. Thus, our asthma control outcomes included: 1) lung function, 2) symptomology, and 3) exacerbations.

Lung function (forced expiratory volume in 1 second (FEV1, percent predicted) and 6 seconds (FEV6, percent predicted), peak flow (percent predicted), forced vital capacity (FVC, percent predicted), and the ratio of FEV1 to FVC) was assessed via spirometry by trained study staff at each clinic visit, collected in triplicate, and the maximum value of each measure at that visit was selected for analyses. Additional measures of peak flow were obtained through daily diary report. Women were instructed in proper use and recording of the peak flow meter at study visit 1, and their technique was reviewed at each study visit. Spirometry protocol followed the National Health and Nutrition Examination Survey Respiratory Health Spirometry Procedures [27]. To account for variation in the timing and number of measurements per woman and to produce clinically interpretable measures by trimester, we calculated individual-level lung function at gestational weeks 14, 28, and delivery using unadjusted linear mixed models with a random intercept and gestational age slope.

Asthma symptom incidence was self-reported in daily diaries and included activity limitation (Did you miss school, work or normal daily activities because of your illness or symptoms?), nighttime symptoms (Did you wake due to difficulty breathing or coughing in the middle of the night?), rescue inhaler use (Did you take any prescription medications?), and respiratory symptoms (Did you experience any of the following symptoms: Wheezing, coughing, shortness of breath, chest tightness, chest pain?). If a woman reported having a cold, the flu, or a sore throat, we did not count symptoms for that day. We then calculated the cumulative incidence rate (days/trimester) of each asthma symptom per trimester based on the number of days that women reported experiencing each outcome per the total number of daily diaries recorded at gestational weeks 14, 28, and delivery.

We additionally examined associations with two measures of asthma exacerbations collected from visit questionnaires: asthma-related medical encounters and asthma attacks. Asthma-related medical encounters were calculated as the sum of reported times women visited a hospital, emergency department/urgent care center or had an unscheduled sick visit to their doctor due to asthma. Asthma attacks were calculated as the sum of reported times women reported experiencing an asthma attack throughout pregnancy per the total number of days of pregnancy. In the first visit questionnaire, women reported asthma attacks and medical encounters from the past year; thus, attacks/encounters from the first study visit were estimated as a proportion of the total number reported from the past year (i.e., number of attacks/encounters x (number of gestational weeks at first study visit / 52 weeks) rounded to the nearest whole number).

Exposure assessment

Maternal height, weight, subscapular skinfolds (mm), and triceps skinfolds (mm) were measured at each study visit by trained study staff following standardized study procedures. Skinfolds were measured using Lange skinfold Calipers (Beta Technology, Inc.) on the right side of the body, collected in triplicate, and averaged for analyses. First trimester sum of skinfolds was calculated as the sum of the subscapular and triceps skinfolds for analyses. Pre-pregnancy BMI (kg/m2) was calculated based on self-reported pre-pregnancy weight and measured height at study visit 1 and categorized as BMI < 25, BMI 25–30, and BMI ≥ 30 [28]. Fifteen women with BMI < 18.5 were included in the BMI < 25 category for analyses.

Additional measures of weight were abstracted from medical records, providing between 2 and 23 (median: 14) weight measures throughout pregnancy. If women had more than 1 weight measure per gestational week, we calculated the mean for that week. To account for variation in the timing and number of measurements per woman and to produce clinically interpretable measures of gestational weight gain by trimester, we calculated individual-level gestational weight gain for each trimester using an unadjusted linear mixed spline model with knots at the end of the first and second trimesters, and a random intercept and slope for gestational age. We then calculated trimester-specific gestational weight gain adequacy based on the rate of gestational weight gain and the Institute of Medicine’s guidelines (inadequate, adequate, excessive; adequate serves as the reference) [29].

Covariates

Covariates for adjustment were selected a priori and included confounders collected by self-report at baseline, daily diaries, and study visits [30, 31]. These covariates included age (years), self-identified race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, Other), household income (quartiles: < $15,000, $15,000-$40,000, $40,000-$100,000, ≥$100,000), marital status (married and/or living with partner, divorced/separated or widowed, single), education (high school or less, Associate’s/some college, Bachelor’s degree, Master’s or advanced degree), parity (nulliparous, multiparous), and pre-pregnancy cigarette smoke exposure (yes/no). Models for gestational weight gain additionally adjusted for BMI, diabetes, and hypertension. All models were additionally adjusted for study site. In sensitivity analyses, we additionally controlled for baseline asthma medication regimen (step 1, step 2, step 3, or step 4+, see S2 Table for definitions) and baseline asthma control according to the Asthma Control Test at visit 1 (well-controlled (score > 19) or poorly-controlled (score ≤ 19)) [25].

Statistical analyses

The aim of this study was to examine maternal body composition and gestational weight gain in relation to asthma control during pregnancy. Multivariable linear regression models examined associations of BMI, skinfolds, and gestational weight gain with mean (95% confidence intervals (CI)) lung function at the end of each trimester. Comparisons are presented as β (95% CI). Multivariable Poisson regression models examined associations of BMI, skinfolds, and gestational weight gain with incidence (days/trimester (95% CI)) of asthma symptoms at the end of each trimester. Comparisons are presented as relative rate ratios (RR (95% CI)). Poisson models included an offset for the number of daily diaries women had completed. Models were run separately for each exposure and each trimester. Models in the second and third trimesters included adjustment for gestational weight gain in prior trimesters.

Asthma exacerbations occurred too infrequently to calculate trimester-specific associations. However, Poisson regression models examined the overall association of each exposure with the number of asthma attacks and medical encounters during pregnancy. These models included an offset for gestational age at delivery.

In secondary analyses, models from primary analyses were re-run to examine associations between all exposures and individual respiratory symptoms (i.e., rate of wheezing, shortness of breath, coughing, chest tightness, or chest pain) and individual exacerbations (i.e., hospitalizations, emergency department/urgent care center, or sick visit to doctor) as our outcomes.

We examine the robustness of our results through two sensitivity analyses. First, we re-ran our primary analysis including additional adjustments for asthma control and medication regimen at baseline. Second, we repeated our primary analysis among women without asthma in order to assess whether our associations may be due to mechanisms that are not asthma-specific (e.g. mechanical restrictions in lung volume).

Missing BMI (n = 58, 19.4%) and cigarette smoking (n = 1, 0.3%) were imputed using 10 multiple chained equations and included all covariates from our primary analysis as well as employment and student status, health insurance, receipt of federal aid (e.g., social security recipient), asthma control variables from the asthma control test, asthma medication regimen, highest recalled weight before pregnancy, lowest recalled weight before pregnancy, pre-pregnancy somatotype, and visit 1 weight. Participant characteristics by BMI category (BMI < 25, BMI 25–30, BMI ≥ 30, missing BMI) are presented in S2 Table.

SAS version 9.4 (Cary, North Carolina, US) and R version 3.6.1 (Vienna, Austria) were used for analyses, and p ≤ 0.05 was used to determine statistical significance. No adjustments were made for multiple comparisons [32].

Results and discussion

Primary analyses were limited to 299 women with asthma, and sensitivity analyses included 101 women without asthma (Fig 1). Women with asthma were on average 29.7 (standard deviation: 5.9) years of age at enrollment and predominantly non-Hispanic Black (n = 157 (52.5%)). Most women with asthma were on a step 1 asthma medication regimen (n = 157 (52.5%)) and had poorly-controlled asthma at enrollment (n = 154 (51.5%)).

Fig 1. Flow diagram of study population for women in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

Fig 1

Mean estimated lung function by pre-pregnancy BMI and gestational weight gain per trimester are presented in Fig 2. Compared to women with BMI < 25, those with BMI ≥ 30 had an approximately 5-unit lower percent predicted FVC across all trimesters of pregnancy (S3 Table). Compared to women with adequate second trimester gestational weight gain, excessive second trimester gestational weight gain was associated with higher second and third trimester percent predicted PEF (βsecond trimester: 6.98 (0.42, 13.54), βthird trimester: 8.78 (0.62, 16.94)). First trimester skinfolds–notably subscapular skinfolds–were negatively associated with percent predicted FEV1, FEV6, and FVC (Table 1).

Fig 2. Estimated means and 95% confidence intervals for lung function per trimester by pre-pregnancy BMI and GWG in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

Fig 2

Abbreviations: % FEV1, percent predicted forced expiratory volume in 1 second; % FEV6, percent predicted forced expiratory volume in 6 seconds; % FVC, percent predicted forced vital capacity; % PEF, percent predicted peak flow; BMI, body mass index; FEV1/FVC, ratio of forced expiratory volume in 1 second to forced vital capacity; GWG, gestational weight gain.

Table 1. Adjusteda association for an IQR-increase in maternal body composition associated with lung function in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

IQRb % FEV1 % FEV6 % FVC % PEF FEV1/FVC
β 95% CI β 95% CI β 95% CI β 95% CI β 95% CI
First trimester
    Subscapular skinfold 13.0 -3.49 -5.75, -1.22 -3.28 -5.78, -0.78 -3.93 -5.91, -1.94 0.39 -2.36, 3.14 -0.003 -0.019, 0.014
    Triceps skinfold 13.0 -1.98 -4.32, 0.36 -2.24 -4.97, 0.50 -3.19 -5.24, -1.15 -0.20 -3.01, 2.61 0.009 -0.008, 0.025
    Sum of skinfolds 22.5 -2.85 -5.03, -0.68 -2.84 -5.29, -0.40 -3.70 -5.60, -1.80 0.11 -2.52, 2.74 0.003 -0.013, 0.019
Second trimester
    Subscapular skinfold 13.0 -3.36 -5.53, -1.18 -3.25 -5.77, -0.73 -3.85 -5.79, -1.90 0.20 -2.48, 2.87 -0.002 -0.019, 0.015
    Triceps skinfold 13.0 -2.10 -4.35, 0.14 -2.10 -4.86, 0.66 -3.13 -5.14, -1.12 -0.43 -3.16, 2.29 0.007 -0.011, 0.024
    Sum of skinfolds 22.5 -2.85 -4.94, -0.75 -2.76 -5.23, -0.30 -3.63 -5.49, -1.76 -0.12 -2.67, 2.44 0.002 -0.014, 0.019
Third trimester
    Subscapular skinfold 13.0 -3.27 -5.42, -1.12 -3.22 -5.78, -0.66 -3.75 -5.66, -1.84 -0.18 -3.01, 2.65 0.000 -0.018, 0.018
    Triceps skinfold 13.0 -2.20 -4.42, 0.02 -1.97 -4.78, 0.83 -3.04 -5.02, -1.07 -0.82 -3.71, 2.06 0.006 -0.013, 0.024
    Sum of skinfolds 22.5 -2.85 -4.91, -0.78 -2.69 -5.20, -0.18 -3.53 -5.36, -1.70 -0.51 -3.22, 2.19 0.003 -0.014, 0.020

Abbreviations: % FEV1, percent predicted forced expiratory volume in 1 second; % FEV6, percent predicted forced expiratory volume in 6 seconds; % FVC, percent predicted forced vital capacity; %PEF, percent predicted peak flow; CI, confidence interval; FEV1/FVC, ratio of forced expiratory volume in 1 second to forced vital capacity; IQR, interquartile range

Bold represents statistically significant (p ≤ 0.05) findings

aModels were adjusted for study site, age, race/ethnicity, household income, marital status, education, parity, and pre-pregnancy cigarette smoke exposure. Models for gestational weight gain were additionally adjusted for pre-pregnancy BMI, diabetes, and hypertension.

bUnits are in millimeters.

Estimated incidence of asthma symptoms by pre-pregnancy BMI and gestational weight gain per trimester are presented in Fig 3. Compared to women with BMI < 25, those with BMI ≥ 30 had more days with night symptoms in the first trimester (RR: 1.66 (1.08, 2.56)) (S4 Table).

Fig 3. Estimated mean days and 95% confidence intervals of asthma symptom burden per trimester by pre-pregnancy BMI and GWG in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

Fig 3

Abbreviations: BMI, body mass index; GWG, gestational weight gain.

Compared to women with adequate first trimester gestational weight gain, inadequate and excess first trimester gestational weight gain were associated with more days with activity limitation in the first trimester (RR: 3.73 (1.18, 11.78), RR: 3.36 (1.15, 9.80), respectively). Excess first trimester gestational weight gain was also associated with more days with rescue inhaler use across all trimesters (RRfirst trimester: 2.57 (1.01, 6.51), RRsecond trimester: 2.89 (1.13, 7.41), RRthird trimester: 3.49 (1.21, 10.02)). Inadequate first trimester gestational weight gain was associated with fewer days with respiratory symptoms in the first trimester (RR: 0.63 (0.42, 0.95)). First trimester triceps skinfolds and sum of skinfolds were positively associated with activity limitation, night symptoms, and rescue inhaler use (Table 2). Results from secondary analyses for individual respiratory symptoms indicated that first trimester skinfolds were positively associated with wheeze and cough, and inadequate first trimester gestational weight gain was associated with fewer days of chest tightness across pregnancy (S5 Table).

Table 2. Adjusteda association for an IQR-increase in maternal body composition associated with incidence of asthma symptoms in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

IQRb Activity limitationc Night symptomsc Rescue inhaler usec Respiratory symptomsc
RR 95% CI RR 95% CI RR 95% CI RR 95% CI
First trimester
    Subscapular skinfold 13.0 1.10 0.84, 1.43 1.16 0.92, 1.47 1.01 0.81, 1.25 1.04 0.91, 1.19
    Triceps skinfold 13.0 1.60 1.23, 2.06 1.39 1.11, 1.73 1.38 1.12, 1.71 1.10 0.96, 1.27
    Sum of skinfolds 22.5 1.33 1.04, 1.69 1.29 1.04, 1.59 1.18 0.97, 1.45 1.07 0.94, 1.22
Second trimester
    Subscapular skinfold 13.0 1.08 0.87, 1.34 1.22 0.98, 1.51 1.07 0.85, 1.34 1.08 0.95, 1.23
    Triceps skinfold 13.0 1.13 0.90, 1.43 1.20 0.97, 1.47 1.40 1.12, 1.75 1.07 0.94, 1.22
    Sum of skinfolds 22.5 1.11 0.90, 1.36 1.22 1.00, 1.49 1.23 1.00, 1.53 1.08 0.96, 1.22
Third trimester
    Subscapular skinfold 13.0 1.16 0.94, 1.44 1.29 1.04, 1.59 1.10 0.87, 1.38 1.06 0.93, 1.21
    Triceps skinfold 13.0 1.17 0.92, 1.48 1.27 1.04, 1.56 1.41 1.12, 1.78 1.07 0.93, 1.22
    Sum of skinfolds 22.5 1.17 0.95, 1.44 1.30 1.07, 1.58 1.26 1.01, 1.57 1.07 0.94, 1.21

Abbreviations: CI, confidence interval; IQR, interquartile range; RR, relative rate ratio

Bold represents statistically significant (p ≤ 0.05) findings

aModels were adjusted for study site, age, race/ethnicity, household income, marital status, education, parity, and pre-pregnancy cigarette smoke exposure. Models for gestational weight gain were additionally adjusted for pre-pregnancy BMI, diabetes, and hypertension.

b Units are in millimeters

cThe number of days women reported experiencing that outcome in daily diaries per the total number of daily diaries per trimester.

Estimated incidence of asthma exacerbations during pregnancy by pre-pregnancy BMI and gestational weight gain are presented in Fig 4. Compared to women with a BMI < 25, women with a BMI 25–30 had fewer asthma-related medical encounters during pregnancy (RR: 0.41 (0.21, 0.82)) (S6 Table). Results from secondary analyses for individual asthma exacerbations indicated that a BMI 25–30 and BMI ≥ 30 were associated with decreased doctor’s visits compared to a BMI < 25 (RR: 0.18 (0.06, 0.53), RR: 0.47 (0.28, 0.79), respectively). First trimester subscapular skinfolds were positively associated with emergency department/urgent care visits (RR: 1.43 (1.05, 1.94)) and negatively associated with doctor’s visits (RR: 0.71 (0.52, 0.97)). Compared to adequate third trimester gestational weight gain, excessive third trimester gestational weight gain was associated with increased emergency department/urgent care visits (RR: 3.08 (1.12, 8.48)).

Fig 4. Estimated mean number and 95% confidence intervals for asthma exacerbations during pregnancy by pre-pregnancy BMI and GWG in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

Fig 4

Abbreviations: BMI, body mass index; GWG, gestational weight gain.

After additional adjustment for baseline asthma control and medication use, results for lung function were similar to our primary analysis, and effects were attenuated for asthma symptom outcomes (S7S9 Tables). Among women without asthma, we did not observe many statistically significant associations, nor were effect sizes similar to analyses among women with asthma (S10 and S11 Tables).

In this prospective cohort study, we report on associations of maternal body composition and gestational weight gain with asthma control during pregnancy. Our findings suggest that women with asthma and higher adiposity (i.e., pre-pregnancy BMI and skinfold thicknesses) were more likely to have a restrictive pattern on spirometry and poor asthma control–as assessed by symptomology and emergency department/urgent care visits–during pregnancy. Gestational weight gain was not related to lung function, but excess gestational weight gain in the first trimester was positively associated with symptomology and excess gestational weight gain in the third trimester was positively associated with emergency department/urgent care visits. These results were consistent across trimesters and similar even with additional adjustment for baseline asthma control and medication use. Notably, these associations were not observed among women without asthma.

Few studies have examined whether pre-pregnancy BMI and gestational weight gain influence asthma control in pregnant populations. Most prior studies have focused only on asthma exacerbations and have observed inconsistent findings. Two studies have reported positive associations [17, 19] and two studies have reported no associations [20, 33] between pre-pregnancy BMI and asthma exacerbations during pregnancy. Similar to our study, Ali et al found that a higher pre-pregnancy BMI was associated with fewer overall asthma exacerbations [16]. In our study, this finding may be due to the strong negative association between maternal obesity and mild asthma exacerbations (i.e., asthma-related doctor’s visits). The obese asthma phenotype is generally characterized by a more severe disease course [10]; thus, women with increased adiposity may be accustomed to poor asthma control and less likely to seek primary care assistance with their asthma during pregnancy. Importantly, this lack of managed care may have contributed to our findings of poor asthma control in these women. Results for severe asthma exacerbations reveal that higher maternal body composition and excessive third trimester gestational weight gain were associated with more emergency department/urgent care visits. In the literature, gestational weight gain has been positively [16], negatively [33], and not associated with asthma exacerbations [17, 20]. Few studies have examined associations for trimester-specific gestational weight gain. Discrepancies in the literature may be due to a number of factors including differences in study populations, definitions of asthma exacerbations, and modelling of gestational weight gain. Given inconsistencies in prior research and the novelty of our findings, replication is needed.

To our knowledge, only one other study has examined associations of maternal body composition and gestational weight gain with asthma control based on symptomology during pregnancy. This study found no associations for pre-pregnancy BMI, and that total gestational weight gain was associated with decreased risk of recurrent uncontrolled asthma [20]. Similarly, we report few associations between pre-pregnancy BMI and asthma symptoms, but that gestational weight gain–in particular excessive first trimester gestational weight gain–was associated with more days of activity limitation and rescue inhaler use. Thus, first trimester may be a critical period during which asthma control during pregnancy may be modified. Unexpectedly, we observed few associations between gestational weight gain and lung function other than improved percent predicted peak flow with excessive second trimester gestational weight gain. Given the lack of biologic plausibility, this finding may be due to chance. Increased rescue inhaler use may therefore not be due to a worsening of lung function; rather, it may represent an increased perception of dyspnea and fatigue associated with pregnancy-related weight gain. Lung function during pregnancy has not been well-described in asthmatic populations. In 2020, Jensen et al reported that women with asthma experienced reduced percent predicted FEV1, percent predicted FVC, and FEV/FVC, which decreased with advancing gestation [34]. In line with our findings, this study reported that higher pre-pregnancy BMI–but not gestational weight gain–was associated with poorer lung function in women with asthma during pregnancy. Given the consistency between our findings and previous studies, it appears that maternal obesity exerts a more notable influence on lung function, and excess gestational weight gain exerts a more notable influence on symptomology, during pregnancy. The current literature linking obesity and asthma does not suggest that the method used to induce changes in weight (i.e., diet, exercise, and/or bariatric surgery) matters more than the extent of the weight change when it comes to influencing asthma control [35]. Nevertheless, the potential role of lifestyle factors and other mechanisms (e.g., weight gain-related pregnancy complications) underlying these associations bear further study.

Our study includes a novel exposure of first trimester skinfold thicknesses which assesses central (subscapular) and regional (triceps) adiposity. We note strong negative associations between higher subscapular skinfolds with poorer lung function, and triceps skinfolds with asthma symptoms, suggesting body composition may be differentially related to different asthma control outcomes. Central adiposity may be linked to reduced lung function through mechanical restrictions to lung volume whereas regional adiposity may be linked to asthma symptoms through inflammatory or cardiometabolic pathways. In non-pregnant populations, skinfolds are reliable measures of body composition [23] and have been associated with poorer lung function [36]. During pregnancy, skinfold assessments to determine body composition is highly debated due to the extensive modifications the maternal unit undergoes during this time [37, 38]. However, skinfolds are commonly used to estimate body composition during pregnancy, are useful in research and clinical settings, and are associated with neonatal outcomes [3739].

Our study also includes a novel sensitivity analyses conducted among women without asthma. These analyses found few differences in lung function measures by body composition or gestational weight gain, though percent predicted FEV6 was lower among women with higher first trimester subscapular skinfolds. This finding is in line with prior studies, which report that pre-pregnancy BMI and gestational weight gain is not associated with differences in lung function across pregnancy in healthy populations [34, 40]. Difference in associations between women with and without asthma may be attributed to differences in sample sizes in these groups; however, effect sizes were also dissimilar. Overall, the contrast between findings among women with and without asthma suggests that mechanical restriction of lung volume or cardiometabolic pathways associated with excess adiposity may not be solely responsible for our observed associations. Rather, other mechanisms may be operating to influence asthma control and restrictive lung function among women with asthma.

Limitations

This study was limited by a small sample size which precluded our ability to conduct subgroup analyses by asthma phenotypes. Participant self-report of certain exposure (pre-pregnancy BMI) or outcome (symptomology, exacerbations) may be subject to measurement error. Self-reported pre-pregnancy weights were highly correlated with first measured pregnancy weights (n = 343, r = 0.98) as well as chart-abstracted pre-pregnancy weights (n = 118, r = 0.94) in our cohort, and missing data imputation for pre-pregnancy BMI allowed us to produce unbiased and efficient estimates for our associations [41]. Symptomology was self-reported in daily diaries, which have been shown to provide more sensitive estimates of asthma control than retrospective questionnaires [42]. Exacerbations–especially for the first trimester, which encompassed a one-year timeframe–were subject to recall bias. However, given the severity of asthma exacerbations and disruption that they would cause, any recall bias of exacerbations is likely limited. Finally, though we account for chronic mediation use at baseline, we did not assess how changes in medication use may have impacted our associations [43].

Strengths

This is a prospective pregnancy cohort with comprehensive data ascertainment across pregnancy in women with and without asthma. Our study expands on prior studies in four key ways. First, we included objective and subjective measures of asthma control including lung function, as well as asthma symptoms. Second, we produced clinically interpretable results for each trimester of pregnancy. Third, we examined associations using body composition in addition to pre-pregnancy BMI [44]. Finally, we included women without asthma to assess whether associations differed in this subgroup.

Conclusions

Poor asthma control affects 57–80% of patients [45] and is modified for more than half of women during pregnancy [7], making identification of risk factors a priority. In this prospective pregnancy cohort of women with and without asthma, we observed asthma-specific associations between higher pre-pregnancy BMI, early pregnancy skinfolds, and first trimester excessive gestational weight gain associated with restrictive changes in lung function and poor asthma control during pregnancy. Despite experiencing decrements in lung function and asthma control, women with an obese asthma phenotype had fewer asthma-related doctor’s visits, suggesting less active management of asthma in this high-risk group. Active asthma management is key to the control of asthma and mitigation of adverse outcomes in pregnancies complicated by asthma [6]. While prenatal care visits are unrelated to asthma, they may provide an opportunity to help pregnant persons with asthma–particularly high-risk individuals with obesity or excess first trimester gestational weight gain–achieve better asthma control.

Supporting information

S1 Table. Eligibility and exclusion criteria in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

(DOCX)

S2 Table. Definitions used to categorize women according to asthma medication regimen in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

(DOCX)

S3 Table. Participant characteristics among women with asthma by pre-pregnancy BMI in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

(DOCX)

S4 Table. Adjusteda association of maternal pre-pregnancy BMI and gestational weight gain with lung function in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

(DOCX)

S5 Table. Adjusteda association between maternal pre-pregnancy BMI and gestational weight gain with incidence of asthma symptom in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

(DOCX)

S6 Table. Adjusteda association between maternal body composition and gestational weight gain with individual respiratory symptoms in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

(DOCX)

S7 Table. Adjusteda association of maternal body composition and gestational weight gain with asthma exacerbations across pregnancy in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

(DOCX)

S8 Table. Sensitivity analyses for adjusteda association of maternal pre-pregnancy BMI and gestational weight gain with lung function in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

(DOCX)

S9 Table. Sensitivity analyses for adjusteda association between maternal pre-pregnancy BMI and gestational weight gain with incidence of asthma symptom in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

(DOCX)

S10 Table. Sensitivity analyses for adjusteda association of maternal body composition and gestational weight gain with asthma exacerbations across pregnancy in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

(DOCX)

S11 Table. Sensitivity analyses for adjusteda association of maternal pre-pregnancy BMI and gestational weight gain with lung function among women without asthma in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

(DOCX)

S12 Table. Sensitivity analyses for adjusteda association between maternal pre-pregnancy BMI and gestational weight gain with incidence of asthma-like symptom among women without asthma in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

(DOCX)

S1 File

(PDF)

S2 File

(PDF)

S3 File

(PDF)

Data Availability

The analytic dataset is now available on BRADS, and is easily accessible with a proposal and DUA filled out as required by NICHD/DIPHR. BRADS datasets are routinely released to outside investigators and this process has worked very well for all parties. All of the internal processes to add the data to the BRADS system are complete, and you should be able to view the instructions for data request at: https://brads.nichd.nih.gov/AccessRequest/AccessRequest/. You can view the new B-WELL-Mom webpage at: https://brads.nichd.nih.gov/OurCollections/BWell/.

Funding Statement

This work was supported by the National Institutes of Health's Intramural Research Program at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (clinical site contracts HHSN275201300013C to Northwestern University, HHSN275201300014C to the University of Alabama at Birmingham; and the Emmes Company for the Data Coordinating Center HHSN275201300026I, HHSN27500001, HHSN275000017). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Centers for Disease Control and Prevention. 2018 National Health Interview Survey (NHIS) Data 2018 [updated December 17, 2019; cited 2019 December 21, 2019]. Available from: https://www.cdc.gov/asthma/nhis/2018/table4-1.htm.
  • 2.Murphy VE, Jensen ME, Gibson PG. Asthma during Pregnancy: Exacerbations, Management, and Health Outcomes for Mother and Infant. Semin Respir Crit Care Med. 2017;38(2):160–73. Epub 2017/06/01. doi: 10.1055/s-0037-1600906 . [DOI] [PubMed] [Google Scholar]
  • 3.Kemppainen M, Lahesmaa-Korpinen AM, Kauppi P, Virtanen M, Virtanen SM, Karikoski R, et al. Maternal asthma is associated with increased risk of perinatal mortality. PLoS One. 2018;13(5):e0197593. Epub 2018/05/19. doi: 10.1371/journal.pone.0197593 ; PubMed Central PMCID: PMC5959067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Mendola P, Laughon SK, Mannisto TI, Leishear K, Reddy UM, Chen Z, et al. Obstetric complications among US women with asthma. Am J Obstet Gynecol. 2013;208(2):127.e1-8. Epub 2012/11/20. doi: 10.1016/j.ajog.2012.11.007 ; PubMed Central PMCID: PMC3557554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Mendola P, Mannisto TI, Leishear K, Reddy UM, Chen Z, Laughon SK. Neonatal health of infants born to mothers with asthma. J Allergy Clin Immunol. 2014;133(1):85–90.e1-4. Epub 2013/08/07. doi: 10.1016/j.jaci.2013.06.012 ; PubMed Central PMCID: PMC3874245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Bonham CA, Patterson KC, Strek ME. Asthma Outcomes and Management During Pregnancy. Chest. 2018;153(2):515–27. Epub 2017/09/05. doi: 10.1016/j.chest.2017.08.029 ; PubMed Central PMCID: PMC5815874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Schatz M, Harden K, Forsythe A, Chilingar L, Hoffman C, Sperling W, et al. The course of asthma during pregnancy, post partum, and with successive pregnancies: a prospective analysis. J Allergy Clin Immunol. 1988;81(3):509–17. Epub 1988/03/01. . [PubMed] [Google Scholar]
  • 8.Cornelius T, Schwartz JE, Balte P, Bhatt SP, Cassano PA, Currow D, et al. A Dyadic Growth Modeling Approach to Examine Associations Between Weight Gain and Lung Function Decline: The NHLBI Pooled Cohorts Study. Am J Epidemiol. 2020. Epub 2020/04/15. doi: 10.1093/aje/kwaa059 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Chen Z, Salam MT, Alderete TL, Habre R, Bastain TM, Berhane K, et al. Effects of Childhood Asthma on the Development of Obesity among School-aged Children. Am J Respir Crit Care Med. 2017;195(9):1181–8. Epub 2017/01/20. doi: 10.1164/rccm.201608-1691OC ; PubMed Central PMCID: PMC5439015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Forno E, Celedon JC. The effect of obesity, weight gain, and weight loss on asthma inception and control. Curr Opin Allergy Clin Immunol. 2017;17(2):123–30. Epub 2016/12/29. doi: 10.1097/ACI.0000000000000339 ; PubMed Central PMCID: PMC5545117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Hossain MJ, Xie L, Lang JE, Wysocki TT, Shaffer TH, Bunnell HT. Piecewise Mixed Effects Model to Compare the Weight-gain Patter ns Before and After Diagnosis of Asthma in Children Younger than 5 Years. J Biom Biostat. 2015;6(4):248. Epub 2015/01/01. doi: 10.4172/2155-6180.1000248 ; PubMed Central PMCID: PMC4772666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Zhang Y, Chen Z, Berhane K, Urman R, Chatzi VL, Breton C, et al. The Dynamic Relationship between Asthma and Obesity in School Children. Am J Epidemiol. 2019;189(6):583–91. Epub 2019/11/13. doi: 10.1093/aje/kwz257 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Granell R, Henderson AJ, Evans DM, Smith GD, Ness AR, Lewis S, et al. Effects of BMI, fat mass, and lean mass on asthma in childhood: a Mendelian randomization study. PLoS Med. 2014;11(7):e1001669. Epub 2014/07/02. doi: 10.1371/journal.pmed.1001669 ; PubMed Central PMCID: PMC4077660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Chen YC, Fan HY, Huang YT, Huang SY, Liou TH, Lee YL. Causal relationships between adiposity and childhood asthma: bi-directional Mendelian Randomization analysis. Int J Obes (Lond). 2019;43(1):73–81. Epub 2018/07/22. doi: 10.1038/s41366-018-0160-8 . [DOI] [PubMed] [Google Scholar]
  • 15.Tashiro H, Shore SA. Obesity and severe asthma. Allergol Int. 2019;68(2):135–42. Epub 2018/12/05. doi: 10.1016/j.alit.2018.10.004 ; PubMed Central PMCID: PMC6540088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Ali Z, Nilas L, Ulrik CS. Excessive gestational weight gain in first trimester is a risk factor for exacerbation of asthma during pregnancy: A prospective study of 1283 pregnancies. J Allergy Clin Immunol. 2018;141(2):761–7. Epub 2017/05/30. doi: 10.1016/j.jaci.2017.03.040 . [DOI] [PubMed] [Google Scholar]
  • 17.Murphy VE, Jensen ME, Powell H, Gibson PG. Influence of Maternal Body Mass Index and Macrophage Activation on Asthma Exacerbations in Pregnancy. J Allergy Clin Immunol Pract. 2017;5(4):981–7 e1. Epub 2017/05/30. doi: 10.1016/j.jaip.2017.03.040 . [DOI] [PubMed] [Google Scholar]
  • 18.Murphy VE, Jensen ME, Robijn AL, Wright TK, Mattes J, Collison A, et al. How Maternal BMI Modifies the Impact of Personalized Asthma Management in Pregnancy. J Allergy Clin Immunol Pract. 2020;8(1):219–28 e3. Epub 2019/07/13. doi: 10.1016/j.jaip.2019.06.033 . [DOI] [PubMed] [Google Scholar]
  • 19.Hendler I, Schatz M, Momirova V, Wise R, Landon M, Mabie W, et al. Association of obesity with pulmonary and nonpulmonary complications of pregnancy in asthmatic women. Obstet Gynecol. 2006;108(1):77–82. Epub 2006/07/04. doi: 10.1097/01.AOG.0000223180.53113.0f . [DOI] [PubMed] [Google Scholar]
  • 20.Grzeskowiak LE, Smith B, Roy A, Dekker GA, Clifton VL. Patterns, predictors and outcomes of asthma control and exacerbations during pregnancy: a prospective cohort study. ERJ Open Res. 2016;2(1). Epub 2016/10/13. doi: 10.1183/23120541.00054-2015 ; PubMed Central PMCID: PMC5005153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2020.
  • 22.Bime C, Nguyen J, Wise RA. Measures of asthma control. Current Opinion in Pulmonary Medicine. 2012;18(1):48–56. doi: 10.1097/MCP.0b013e32834db0f2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Ketel IJ, Volman MN, Seidell JC, Stehouwer CD, Twisk JW, Lambalk CB. Superiority of skinfold measurements and waist over waist-to-hip ratio for determination of body fat distribution in a population-based cohort of Caucasian Dutch adults. Eur J Endocrinol. 2007;156(6):655–61. Epub 2007/05/31. doi: 10.1530/EJE-06-0730 . [DOI] [PubMed] [Google Scholar]
  • 24.National Asthma Educatio and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. National Heart, Lung, and Blood Institute, 2007.
  • 25.Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113(1):59–65. Epub 2004/01/10. doi: 10.1016/j.jaci.2003.09.008 . [DOI] [PubMed] [Google Scholar]
  • 26.ACOG Committee on Practice Bulletins. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecolosits Number 90. Obstet Gynecol. February 2008;111:457–64. doi: 10.1097/AOG.0b013e3181665ff4 [DOI] [PubMed] [Google Scholar]
  • 27.Prevention CfDCa. National Heath and Nutrition Examination Survey (NHANES) Respiratory Health Spirometry Procedures Manual. http://www.cdc.gov/nchs/data/nhanes/nhanes_07_08/spirometry.pdf2008.
  • 28.Shin D, Chung H, Weatherspoon L, Song WO. Validity of prepregnancy weight status estimated from self-reported height and weight. Matern Child Health J. 2014;18(7):1667–74. Epub 2013/12/18. doi: 10.1007/s10995-013-1407-6 . [DOI] [PubMed] [Google Scholar]
  • 29.Kominiarek MA, Peaceman AM. Gestational weight gain. Am J Obstet Gynecol. 2017;217(6):642–51. Epub 2017/05/28. doi: 10.1016/j.ajog.2017.05.040 ; PubMed Central PMCID: PMC5701873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Textor J, van der Zander B, Gilthorpe MS, Liskiewicz M, Ellison GT. Robust causal inference using directed acyclic graphs: the R package ’dagitty’. Int J Epidemiol. 2016;45(6):1887–94. Epub 2017/01/17. doi: 10.1093/ije/dyw341 . [DOI] [PubMed] [Google Scholar]
  • 31.Cole SR, Platt RW, Schisterman EF, Chu H, Westreich D, Richardson D, et al. Illustrating bias due to conditioning on a collider. Int J Epidemiol. 2010;39(2):417–20. Epub 2009/11/21. doi: 10.1093/ije/dyp334 ; PubMed Central PMCID: PMC2846442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43–6. Epub 1990/01/01. . [PubMed] [Google Scholar]
  • 33.Murphy VE, Gibson P, Talbot PI, Clifton VL. Severe asthma exacerbations during pregnancy. Obstet Gynecol. 2005;106(5 Pt 1):1046–54. Epub 2005/11/02. doi: 10.1097/01.AOG.0000185281.21716.02 . [DOI] [PubMed] [Google Scholar]
  • 34.Jensen ME, Robijn AL, Gibson PG, Oldmeadow C, Managing Asthma in Pregnancy study collaborative g, Breathing for Life Trial collaborative g, et al. Longitudinal Analysis of Lung Function in Pregnant Women with and without Asthma. J Allergy Clin Immunol Pract. 2020. Epub 2020/11/17. doi: 10.1016/j.jaip.2020.10.061 . [DOI] [PubMed] [Google Scholar]
  • 35.Miethe S, Karsonova A, Karaulov A, Renz H. Obesity and asthma. Journal of Allergy and Clinical Immunology. 2020;146(4):685–93. doi: 10.1016/j.jaci.2020.08.011 [DOI] [PubMed] [Google Scholar]
  • 36.Byberg KK, Mikalsen IB, Eide GE, Forman MR, Juliusson PB, Oymar K. The associations between weight-related anthropometrics during childhood and lung function in late childhood: a retrospective cohort study. BMC Pulm Med. 2018;18(1):10. Epub 2018/01/21. doi: 10.1186/s12890-017-0567-3 ; PubMed Central PMCID: PMC5775530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Widen EM, Gallagher D. Body composition changes in pregnancy: measurement, predictors and outcomes. Eur J Clin Nutr. 2014;68(6):643–52. Epub 2014/03/29. doi: 10.1038/ejcn.2014.40 ; PubMed Central PMCID: PMC4078736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Most J, Marlatt KL, Altazan AD, Redman LM. Advances in assessing body composition during pregnancy. Eur J Clin Nutr. 2018;72(5):645–56. Epub 2018/05/12. doi: 10.1038/s41430-018-0152-8 ; PubMed Central PMCID: PMC6348859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Pugh SJ, Ortega-Villa AM, Grobman W, Hinkle SN, Newman RB, Hediger M, et al. Longitudinal changes in maternal anthropometry in relation to neonatal anthropometry. Public Health Nutr. 2019;22(5):797–804. Epub 2019/02/12. doi: 10.1017/S1368980018003749 ; PubMed Central PMCID: PMC6440828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Grindheim G, Toska K, Estensen ME, Rosseland LA. Changes in pulmonary function during pregnancy: a longitudinal cohort study. BJOG. 2012;119(1):94–101. Epub 2011/10/19. doi: 10.1111/j.1471-0528.2011.03158.x . [DOI] [PubMed] [Google Scholar]
  • 41.Perkins NJ, Cole SR, Harel O, Tchetgen Tchetgen EJ, Sun B, Mitchell EM, et al. Principled Approaches to Missing Data in Epidemiologic Studies. Am J Epidemiol. 2018;187(3):568–75. Epub 2017/11/23. doi: 10.1093/aje/kwx348 ; PubMed Central PMCID: PMC5860376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Okupa AY, Sorkness CA, Mauger DT, Jackson DJ, Lemanske RF Jr., Daily diaries vs retrospective questionnaires to assess asthma control and therapeutic responses in asthma clinical trials: is participant burden worth the effort? Chest. 2013;143(4):993–9. Epub 2013/01/05. doi: 10.1378/chest.12-1055 ; PubMed Central PMCID: PMC3616688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Robijn AL, Jensen ME, McLaughlin K, Gibson PG, Murphy VE. Inhaled corticosteroid use during pregnancy among women with asthma: A systematic review and meta-analysis. Clin Exp Allergy. 2019;49(11):1403–17. Epub 2019/07/30. doi: 10.1111/cea.13474 . [DOI] [PubMed] [Google Scholar]
  • 44.Sideleva O, Suratt BT, Black KE, Tharp WG, Pratley RE, Forgione P, et al. Obesity and asthma: an inflammatory disease of adipose tissue not the airway. Am J Respir Crit Care Med. 2012;186(7):598–605. Epub 2012/07/28. doi: 10.1164/rccm.201203-0573OC ; PubMed Central PMCID: PMC3480522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Abrahamsen R, Gundersen GF, Svendsen MV, Klepaker G, Kongerud J, Fell AKM. Possible risk factors for poor asthma control assessed in a cross-sectional population-based study from Telemark, Norway. PLoS One. 2020;15(5):e0232621. Epub 2020/05/13. doi: 10.1371/journal.pone.0232621 ; PubMed Central PMCID: PMC7217450. [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Kelli K Ryckman

5 Nov 2021

PONE-D-21-21560Maternal body composition and gestational weight gain in relation to asthma control during pregnancyPLOS ONE

Dear Dr. Mendola,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Dec 20 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Kelli K Ryckman

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information. If the original language is written in non-Latin characters, for example Amharic, Chinese, or Korean, please use a file format that ensures these characters are visible.

3. Please state whether you validated the questionnaire prior to testing on study participants. Please provide details regarding the validation group within the methods section.

4. Thank you for stating the following in the Acknowledgments/Funding Section of your manuscript:

“This work was supported by the National Institutes of Health's Intramural Research Program at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (clinical site contracts HHSN275201300013C to Northwestern University, HHSN275201300014C to the University of Alabama at Birmingham; and the Emmes Company for the Data Coordinating Center HHSN275201300026I, HHSN27500001, HHSN275000017).”

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“This work was supported by the National Institutes of Health's Intramural Research Program at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (clinical site contracts HHSN275201300013C to Northwestern University, HHSN275201300014C to the University of Alabama at Birmingham; and the Emmes Company for the Data Coordinating Center HHSN275201300026I, HHSN27500001, HHSN275000017).  The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

5. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

6. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

7. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is a well written paper, and novel study examining body composition and gestational weight gain and their relationship with asthma control during pregnancy.

What was the rationale for examining FEV6?

Reviewer #2: This is a prospective cohort of 299 women examining the associations between body composition and weight gain with asthma during pregnancy. The manuscript is well written and shows that increased weight and exessive weight gain in the first trimester were associated woth lung function during pregnancy.

I only have some minor comments.

Materials and Methods

In regards to the population; did you account for women twins or triplets? Were they included in the cohort?

In the last paragraph on page 7 (rows 145-148) you state that women reported asthma attacks and medical encounters from the past year; did you also have medical records to confirm this or was it just by participants recall?

Results

Do you have any explanation for the improved PEF in women with exessive weight gain? (Table S3)

Dicsussion

The FEV1/FVC seems to be unaltered during pregnancy regardless of weight gain. Still, women tend to have more asthma symptoms with increased weight. Do you have any comments on this? Is the symptomology reflecting asthma? Or something else?

The conclusion is not very clear. Now it includes parts that should be in the introduction (background) as well as parts that should be in the first paragraph of the discussion. I suggest you leave those things out and instead include something more similar to what you have in the abstract.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Apr 20;17(4):e0267122. doi: 10.1371/journal.pone.0267122.r002

Author response to Decision Letter 0


25 Mar 2022

RESPONSE TO REVIEWERS

Reviewer #1: This is a well written paper, and novel study examining body composition and gestational weight gain and their relationship with asthma control during pregnancy.

What was the rationale for examining FEV6?

Response: FEV6 was included as part of the original study protocol based on prior studies in pregnant populations finding FEV6 to be highly correlated with FVC whilst being easier, more achievable, more reproducible, and less physically demanding1. Its inclusion in the analysis was to completely represent all measures from spirometry.

1. Zairina E, Abramson MJ, McDonald CF, et al. A prospective cohort study of pulmonary function during pregnancy in women with and without asthma. J Asthma. 2016;53(2):155-63. doi:10.3109/02770903.2015.1080268

Reviewer #2: This is a prospective cohort of 299 women examining the associations between body composition and weight gain with asthma during pregnancy. The manuscript is well written and shows that increased weight and excessive weight gain in the first trimester were associated with lung function during pregnancy.

I only have some minor comments.

Materials and Methods

In regards to the population; did you account for women twins or triplets? Were they included in the cohort?

Response: To be eligible for study participation, participants had to have a singleton pregnancy. We have added study eligibility criteria to our supplement as S1 Table and reference this table on page 6, line 108 of the revised manuscript:

“Medical record review was used to identify potentially eligible participants, who were then screened for eligibility (S1 Table) and consent”.

In the last paragraph on page 7 (rows 145-148) you state that women reported asthma attacks and medical encounters from the past year; did you also have medical records to confirm this or was it just by participants recall?

Response: A chart abstraction was completed for participants during their time in the study and included encounters within a given hospital system. Thus, chart abstractions were unfortunately not able to detail a complete history of asthma attacks and/or medical encounters.

However, you bring up a good point about the limitations of this measure. We have thus added additional language to the limitations section (page 21, lines 389-402) on self-reported measurement error. This section now reads,

“This study was limited by a small sample size which precluded our ability to conduct subgroup analyses by asthma phenotypes. Participant self-report of certain exposure (pre-pregnancy BMI) or outcome (symptomology, exacerbations) may be subject to measurement error. Self-reported pre-pregnancy weights were highly correlated with first measured pregnancy weights (n=343, r=0.98) as well as chart-abstracted pre-pregnancy weights (n=118, r=0.94) in our cohort, and missing data imputation for pre-pregnancy BMI allowed us to produce unbiased and efficient estimates for our associations[41]. Symptomology was self-reported in daily diaries, which have been shown to provide more sensitive estimates of asthma control than retrospective questionnaires[42]. Exacerbations – especially for the first trimester, which encompassed a one-year timeframe – were subject to recall bias. However, given the severity of asthma exacerbations and disruption that they would cause, any recall bias of exacerbations is likely limited. Finally, though we account for chronic mediation use at baseline, we did not assess how changes in medication use may have impacted our associations[43].”

Results

Do you have any explanation for the improved PEF in women with excessive weight gain? (Table S3)

Response: We agree that this is a curious finding. These associations are present only for the excessive second trimester gestational weight gain; though not significant, first and third trimester excessive gestational weight gain were associated with reduced PEF. In childhood, weight gain is associated with greater lung volumes due to lung growth via IGF-1 and other factors. In adult women, this would not make too much sense. From the pregnancy literature (which is admittedly limited), there is no strong explanation. More notable, our clinical authors do not see a reason for the finding, and we are hesitant to speculate. We have added some additional language to the discussion on page 19, lines 344-346 clarifying this:

“Unexpectedly, we observed few associations between gestational weight gain and lung function other than improved percent predicted peak flow with excessive second trimester gestational weight gain. Given the lack of biologic plausibility, this finding may be due to chance.”

Discussion

The FEV1/FVC seems to be unaltered during pregnancy regardless of weight gain. Still, women tend to have more asthma symptoms with increased weight. Do you have any comments on this? Is the symptomology reflecting asthma? Or something else?

Response: Our findings are present only among participants with asthma, suggesting that the mechanisms driving this association are asthma-specific. Further, the main symptoms influenced were activity limitation, night symptoms, and rescue inhaler use; respiratory symptoms – which may be more obviously linked to lung function – were unaffected. Several potential mechanisms may explain our findings. The means by which participants regulate weight changes (e.g., exercise, diet) may differ by asthma status, and this may be the true factor influencing symptomology in participants with asthma. Asthma may be co-occurring with weight gain-related pregnancy complications (e.g., hypertensive disorders of pregnancy) to influence symptomology. Along the lines of your suggestion, symptomology may be reflecting something other than asthma (e.g., increased perception of dyspnea and fatigue associated with pregnancy-related weight gain, which may be felt more keenly among participants with asthma).

We have discussed lifestyle factors (page 20, lines 355-359), pregnancy-related dyspnea and fatigue (page 19, lines 345-347), and now briefly reference weight gain-related pregnancy complications on page 20, lines 358-359.

The conclusion is not very clear. Now it includes parts that should be in the introduction (background) as well as parts that should be in the first paragraph of the discussion. I suggest you leave those things out and instead include something more similar to what you have in the abstract.

Response: We have modified the Conclusions (Page 22, lines 407-422) to now read,

“Poor asthma control affects 57-80% of patients [44] and is modified for more than half of women during pregnancy[7], making identification of risk factors a priority. In this prospective pregnancy cohort of women with and without asthma, we observed asthma-specific associations between higher pre-pregnancy BMI, early pregnancy skinfolds, and excessive first trimester gestational weight gain associated with restrictive changes in lung function and poor asthma control during pregnancy. Despite experiencing decrements in lung function and asthma control, women with an obese asthma phenotype had fewer asthma-related doctor’s visits, suggesting less active management of asthma in this high-risk group. Active asthma management is key to the control of asthma and mitigation of adverse outcomes in pregnancies complicated by asthma[6]. While prenatal care visits are unrelated to asthma, they may provide an opportunity to help pregnant persons with asthma – particularly high-risk individuals with obesity or excess first trimester gestational weight gain – achieve better asthma control."

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Kelli K Ryckman

4 Apr 2022

Maternal body composition and gestational weight gain in relation to asthma control during pregnancy

PONE-D-21-21560R1

Dear Dr. Mendola,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Kelli K Ryckman

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Kelli K Ryckman

7 Apr 2022

PONE-D-21-21560R1

Maternal body composition and gestational weight gain in relation to asthma control during pregnancy

Dear Dr. Mendola:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Kelli K Ryckman

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Eligibility and exclusion criteria in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

    (DOCX)

    S2 Table. Definitions used to categorize women according to asthma medication regimen in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

    (DOCX)

    S3 Table. Participant characteristics among women with asthma by pre-pregnancy BMI in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

    (DOCX)

    S4 Table. Adjusteda association of maternal pre-pregnancy BMI and gestational weight gain with lung function in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

    (DOCX)

    S5 Table. Adjusteda association between maternal pre-pregnancy BMI and gestational weight gain with incidence of asthma symptom in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

    (DOCX)

    S6 Table. Adjusteda association between maternal body composition and gestational weight gain with individual respiratory symptoms in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

    (DOCX)

    S7 Table. Adjusteda association of maternal body composition and gestational weight gain with asthma exacerbations across pregnancy in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

    (DOCX)

    S8 Table. Sensitivity analyses for adjusteda association of maternal pre-pregnancy BMI and gestational weight gain with lung function in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

    (DOCX)

    S9 Table. Sensitivity analyses for adjusteda association between maternal pre-pregnancy BMI and gestational weight gain with incidence of asthma symptom in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

    (DOCX)

    S10 Table. Sensitivity analyses for adjusteda association of maternal body composition and gestational weight gain with asthma exacerbations across pregnancy in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

    (DOCX)

    S11 Table. Sensitivity analyses for adjusteda association of maternal pre-pregnancy BMI and gestational weight gain with lung function among women without asthma in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

    (DOCX)

    S12 Table. Sensitivity analyses for adjusteda association between maternal pre-pregnancy BMI and gestational weight gain with incidence of asthma-like symptom among women without asthma in the Breathe-Wellbeing, Environment, Lifestyle, and Lung Function Study, 2015–2019, USA.

    (DOCX)

    S1 File

    (PDF)

    S2 File

    (PDF)

    S3 File

    (PDF)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    The analytic dataset is now available on BRADS, and is easily accessible with a proposal and DUA filled out as required by NICHD/DIPHR. BRADS datasets are routinely released to outside investigators and this process has worked very well for all parties. All of the internal processes to add the data to the BRADS system are complete, and you should be able to view the instructions for data request at: https://brads.nichd.nih.gov/AccessRequest/AccessRequest/. You can view the new B-WELL-Mom webpage at: https://brads.nichd.nih.gov/OurCollections/BWell/.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES